Updated data show AYVAKIT® (avapritinib) was safe and effective for long-term treatment of ISM, with sustained symptom and quality-of-life benefit and no new safety signals with multiple years of ...

Enhertu is supplied in a single-dose vial containing 100mg of lyophilized powder for reconstitution and further dilution prior to IV infusion. Patients should be selected for treatment with ...

Enhertu is approved for HR-positive, HER2-low or -ultralow metastatic breast cancer, expanding treatment options for these patients. DESTINY-Breast06 trial showed Enhertu reduced disease progression ...

In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every ...

AstraZeneca and Daiichi Sankyo have claimed approval in the EU for Enhertu as a second-line therapy for HER2-positive metastatic breast cancer, moving the drug up the treatment pathway.

Enhertu, an oncology drug by AstraZeneca, led new drug sales in 2024 with Rs 58 crore, reflecting rising cancer cases. Over 3,100 new brands collectively earned Rs 1,097 crore, with significant ...

All patients with breast cancer who may be candidates for antibody-drug conjugate therapy should undergo HER2 testing to determine eligibility for Enhertu (fam-trastuzumab deruxtecan-nxki) — an agent ...

In a significant development for India's pharmaceutical industry, Enhertu (trastuzumab deruxtecan), an oncology drug marketed by AstraZeneca, recorded the highest sales among newly launched drugs ...

billboard hot 100™ the week’s most popular current songs across all genres, ranked by streaming activity data by online music sources tracked by luminate, radio airplay audience impressions as ...

Here's the NOW That's What I Call Music! 120 tracklist in full ...

From the March/April 2025 issue of Car and Driver. You'd think the sight of a new MG might attract more attention, whether it was spied carving up the winding roads of rural Scotland or whizzing ...